Literature DB >> 23017513

Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance.

Kate D Linton1, Derek J Rosario, Francis Thomas, Naomi Rubin, John R Goepel, Maysam F Abbod, James W F Catto.   

Abstract

PURPOSE: We determined the risk of disease specific mortality in patients with primary, low risk, noninvasive (G1pTa) bladder cancer and compared it to disease specific mortality in age and gender matched general populations.
MATERIALS AND METHODS: We identified all patients with primary low risk cancer at our institution. We excluded those with adverse pathological features and then matched histopathology, pharmacy, hospital episode and Cancer Registry records. We reviewed case notes on patients with subsequent muscle invasion (progression) or disease specific mortality. Patients underwent post-resection surveillance and treatment using standard regimens. National and regional disease specific mortality rates were calculated from appropriate data.
RESULTS: A total of 699 patients met study inclusion criteria. Median followup was 61 months (IQR 24-105). Of the patients 17 (2.4%) died of bladder cancer, including 13 of 14 with progression to muscle invasion and 4 of 19 with grade progression to high grade, nonmuscle invasive disease. On Cox regression analyses low grade dysplasia in the initial resection specimen and tumor weight were associated with disease specific mortality (p <0.003). Disease specific mortality in these patients was 5 times the background rate in matched populations. Limitations of this study include its retrospective nature and the low frequency of adverse events.
CONCLUSIONS: Patients with low risk bladder cancer rarely progress to muscle invasion but they are at higher risk for disease specific mortality than the general population. Current surveillance regimens appear ineffective for detecting progression in time to alter prognosis.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23017513     DOI: 10.1016/j.juro.2012.09.084

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  A Festschrift in Honor of Edward M. Messing, MD, FACS.

Authors:  Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump
Journal:  Bladder Cancer       Date:  2018-10-03

2.  An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer.

Authors:  Valeria Panebianco; Ettore De Berardinis; Giovanni Barchetti; Giuseppe Simone; Constantino Leonardo; Marcello Domenico Grompone; Maurizio Del Monte; Davide Carano; Michele Gallucci; James Catto; Carlo Catalano
Journal:  Eur Radiol       Date:  2017-02-08       Impact factor: 5.315

Review 3.  Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma.

Authors:  Rao S Mandalapu; Mesut Remzi; Theo M de Reijke; Vitaly Margulis; J Palou; A Kapoor; Ofer Yossepowitch; Jonathan Coleman; Olivier Traxer; J Kyle Anderson; James Catto; Jean de la Rosette; Timothy O'Brien; Anthony Zlotta; Surena F Matin
Journal:  World J Urol       Date:  2016-05-27       Impact factor: 4.226

4.  Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data.

Authors:  Goutham Vemana; Eric H Kim; Sam B Bhayani; Joel M Vetter; Seth A Strope
Journal:  Urology       Date:  2016-05-24       Impact factor: 2.649

5.  Urothelial Bladder Cancer Urinary Biomarkers.

Authors:  Aidan P Noon; Alexandre R Zlotta
Journal:  EJIFCC       Date:  2014-04-28

6.  Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer.

Authors:  Johannes Breyer; Sanzhar Shalekenov; Atiqullah Aziz; Bastiaan W G van Rhijn; Johannes Bründl; Eva Lausenmeyer; Julius Schäfer; Stefan Denzinger; Christian Giedl; Maximilian Burger; Arndt Hartmann; Matthias Evert; Wolfgang Otto
Journal:  Bladder Cancer       Date:  2017-07-27

Review 7.  Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).

Authors:  Valeria Panebianco; Yoshifumi Narumi; Ersan Altun; Bernard H Bochner; Jason A Efstathiou; Shaista Hafeez; Robert Huddart; Steve Kennish; Seth Lerner; Rodolfo Montironi; Valdair F Muglia; Georg Salomon; Stephen Thomas; Hebert Alberto Vargas; J Alfred Witjes; Mitsuru Takeuchi; Jelle Barentsz; James W F Catto
Journal:  Eur Urol       Date:  2018-05-10       Impact factor: 20.096

8.  Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients.

Authors:  A P Noon; P C Albertsen; F Thomas; D J Rosario; J W F Catto
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

9.  MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer.

Authors:  Ross M Drayton; Stefan Peter; Katie Myers; Saiful Miah; Ewa Dudziec; Helen E Bryant; James W F Catto
Journal:  Oncotarget       Date:  2014-08-15

10.  Health-related quality of life after treatment for bladder cancer in England.

Authors:  Samantha J Mason; Amy Downing; Penny Wright; Luke Hounsome; Sarah E Bottomley; Jessica Corner; Mike Richards; James W Catto; Adam W Glaser
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.